US President Trump says if the US didn't buy Swiss watches anymore, would save USD 40bln; touts pharma company investments in the US

Off-the-cuff trade remarks of this kind fit a well-worn pattern in which bilateral deficits are framed as savings to be captured by curtailing imports, a framing that has historically preceded tariff threats rather than reflecting any actual mechanism by which the saving accrues. Past episodes of deficit-focused rhetoric aimed at a single country have tended to function as negotiating positioning, with the sequence typically running from public comment, to formal tariff process or exemption talks, to either escalation or a face-saving settlement; the first read on any named-sector remark is which of those branches it sits on. The two threads here behave differently: the Swiss watches reference is deficit arithmetic aimed at a surplus counterpart, while the pharma investment line is the recurring onshoring claim, where company announcements of US capacity have often repackaged pre-existing plans and the real tell is whether commitments are new capital or re-labelled. CHF-exposed luxury and pharma names have historically been the transmission channel for sector-specific trade rhetoric, with the FX leg secondary unless rhetoric hardens into scheduled measures. What is worth watching is any follow-through into formal process, since unscripted remarks of this kind have as often faded as escalated.